Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer

Genes Chromosomes and Cancer

Volumn 48, Issue 11, 2009, Pages 983-992

  Narayan, Gopeshwar ^a   Scotto, Luigi ^a   Neelakantan, Vijayalakshmi ^a   Kottoor, Sherine H ^a   Wong, Ada Ho Yan ^b   Loke, Shee Loong ^c   Mansukhani, Mahesh ^a   Pothuri, Bhavana ^a   Wright, Jason D ^a   Kaufmann, Andreas M ^d   Schneider, Achim ^d   Arias Pulido, Hugo ^e,f   Tao, Qian ^b   Murty, Vundavalli V ^a  

^a Department of Medicine   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c St Teresa's Hospital   (Hong Kong)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Instituto Nacional de Cancerología   (Colombia)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; PROTEIN PCDH 10; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL LINE; CHROMOSOME 4; CHROMOSOME 4Q; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOSOMY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

CADHERINS; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 4; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMANS; MONOSOMY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; UTERINE CERVICAL NEOPLASMS;

EID: 70349324480     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20703     Document Type: Article

References (26)

1. Backsch C, Wagenbach N, Nonn M, Leistritz S, Stanbridge E, Schneider A, Durst M. 2001. Microcell-mediated transfer of chromosome 4 into HeLa cells suppresses telomerase activity. Genes Chromosomes Cancer 31:196-198. (Pubitemid 32411046)
2. Backsch C, Rudolph B, Kuhne-Heid R, Kalscheuer V, Bartsch O, Jansen L, Beer K, Meyer B, Schneider A, Durst M. 2005. A region on human chromosome 4 (q35.1->qter) induces senescence in cell hybrids and is involved in cervical carcinogenesis. Genes Chromosomes Cancer 43:260-272. (Pubitemid 40726871)
3. Frank M, Kemler R. 2002. Protocadherins. Curr Opin Cell Biol 14:557-562.
4. Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, Cavenee WK. 1996. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: Subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci USA 93:6704-6709. (Pubitemid 26230373)
5. Imoto I, Izumi H, Yokoi S, Hosoda H, Shibata T, Hosoda F, Ohki M, Hirohashi S, Inazawa J. 2006. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res 66:4617-4626.
6. Jeanes A, Gottardi CJ, Yap AS. 2008. Cadherins and cancer: How does cadherin dysfunction promote tumor progression? Oncogene 27:6920-6929.
7. Knudson AG, Jr., Strong LC. 1972. Mutation and cancer: Neuroblastoma and pheochromocytoma. Am J Hum Genet 24:514-532.
8. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, Skegg DC. 2008. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol 9:425-434.
9. Mitra AB, Murty VV, Li RG, Pratap M, Luthra UK, Chaganti RS. 1994. Allelotype analysis of cervical carcinoma. Cancer Res 54: 4481-4487.
10. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, Schneider A, Terry MB, Mansukhani M, Murty VV. 2003. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: Its relationship to clinical outcome. Mol Cancer 2:24. (Pubitemid 38751473)
11. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV. 2004. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer 4:5. (Pubitemid 38851368)
12. Schiffman M, Rodriguez AC. 2008. Heterogeneity in CIN3 diagnosis. Lancet Oncol 9:404-406.
13. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Murty VV. 2008a. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. Genes Chromosomes Cancer 47:755-765.
14. Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Schneider A, Arias- Pulido H, Murty VV. 2008b. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target overexpressed genes, including Drosha. Mol Cancer 7:58.
15. Singh RK, Indra D, Mitra S, Mondal RK, Basu PS, Roy A, Roychowdhury S, Panda CK. 2007. Deletions in chromosome 4 differentially associated with the development of cervical cancer: Evidence of slit2 as a candidate tumor suppressor gene. Hum Genet 122:71-81. (Pubitemid 47040575)
16. Syrjanen KJ. 1996. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 65:45-53.
17. The ASCUS-LSIL Triage Study (ALTS) Group. 2003. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188:1383-1392.
18. Waggoner SE. 2003. Cervical cancer. Lancet 361:2217-2225.
19. Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T, Wiestler OD. 2005. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 7:193-199. (Pubitemid 40411631)
20. Yagi T. 2008. Clustered protocadherin family. Dev Growth Differ 50 (Suppl 1):S131-S140.
21. Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT, Tao Q. 2006. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25:1070-1080. (Pubitemid 43277014)
22. Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, Ambinder RF, Chan AT, Tao Q. 2007. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol 136:829-832. (Pubitemid 46348417)
23. Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, Hibshoosh H, Tycko B, Parsons R. 2008. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 27: 4657-4665.
24. Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, Tian LW, Wong YP, Tong JH, Ying JM, Jin H, To KF, Chan FK, Sung JJ. 2009. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 136:640-651.
25. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, Martinez A, Narayan G, Kirsch I, Franklin W, Hirsch F, Birrer M, Cuttitta F. 2008. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 118:640-650. (Pubitemid 351206553)
26. zur Hausen H. 2002. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.